CME Sponsor:
Imedex
 
Location:
The Waldorf=Astoria
New York, New York

Faculty:
Morton Coleman, MD
Chair
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York-Presbyterian Hospital/ Weill Cornell Medical Center
New York, New York

John P. Leonard, MD
Chair
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York-Presbyterian Hospital/ Weill Cornell Medical Center
New York, New York

Ruben Niesvizky, MD
Chair
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York-Presbyterian Hospital/ Weill Cornell Medical Center
New York, New York

Richard R. Furman, MD
Chair
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York-Presbyterian Hospital/ Weill Cornell Medical Center
New York, New York

Edwin Alyea, MD
Harvard University
Dana-Farber Cancer Institute
Boston, Massachusetts

Kenneth C. Anderson, MD
Harvard University
Dana-Farber Cancer Institute
Boston, Massachusetts

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, Minnesota

Francis P. Arena, MD
The Sass Foundation
New York, New York

Bart Barlogie, MD, PhD
University of Arkansas Medical Center
Little Rock, Arkansas

James R. Berenson, MD
Institute for Myeloma and Bone Cancer Research    
West Hollywood, California

Joan Bladé, MD
University of Barcelona Hospital Clinic
Barcelona, Spain

Selina Chen-Kiang, MD
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Bruce D. Cheson, MD
Georgetown University Hospital
Washington, District of Columbia

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Myron Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

Faith E. Davies, MBBBch, MD, MRCP,  FRCPath  
Institute of Cancer Research and Royal Marsden Hospital     
Sutton, United Kingdom

Volker Diehl, MD, PhD
University Hospital of Cologne
Hohen Neuendorf, Germany

Meletios-Athanasios Dimopoulos, MD
University of Athens School of Medicine  
Athens, Greece

Brian G. M. Durie, MD*
Cedars-Sinai Samuel Oschin Cancer Center  
Los Angeles, California

Rebecca Elstrom, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Scott Ely, MD, MPH
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Jonathan Friedberg, MD
James P. Wilmot Cancer Center
University of Rochester
Rochester, New York

Sergio A. Giralt, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York

Peter Johnson, MD
Cancer Research UK Center
South Hampton, United Kingdom

Brad Kahl, MD
University of Wisconsin
Carbone Comprehensive Cancer Center
Madison, Wisconsin

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Michael J. Keating, MB, BS
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Thomas J. Kipps, MD, PhD
University of California, San Diego
Moores Cancer Center
LaJolla, California

Suzanne Lentzsch, MD, PhD
University of Pittsburgh
School of Medicine and Cancer Institute
Pittsburgh, Pennsylvania

Tomer Mark, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Peter Martin, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Ari Melnick, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Constantine S. Mitsiades, MD, PhD
Harvard University
Dana-Farber Cancer Institute
Boston, Massachusetts

Craig Moskowitz, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Roger Pearse, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Kanti Rai, MD
North Shore Long Island Jewish Medical Center
New Hyde Park, New York

Noopor S. Raje, MD
Harvard University
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD
Harvard University
Dana-Farber Cancer Institute
Boston, Massachusetts

Lisa M. Rimsza, MD
University of Arizona
Tucson, Arizona

Ritz Shaknovich, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Wyndham Wilson, MD, PhD
National Cancer Institute
Bethesda, Maryland

Number of Credits:
18.5 of AMA PRA Category 1 Credits™
 
Registration:
Early (payment received by 8/18/11) $445
Discounted (payment received by 10/13/11) $545
Regularly (payment received after 10/13/11) $645
Nurses/Residents/Students* $145
Pharmacists* $345
 
*proof of eligibility must accompany registration, and cannot be combined with any other discount

For easy registration or any questions, please call toll free at 1-855-276-6855.
 
Link

Detailed Description:
This educational activity is specifically designed for hematologists, oncologists, and other healthcare professionals involved and/or interested in the therapeutic management of patients with lymphoproliferative and other plasma cell disorders.

Using a dynamic approach that features clinical controversies, exciting debates, and intriguing lectures involving examinations of current treatment regimens, attendees will receive a thorough understanding behind the evolution of thought and therapy of lymphoma and myeloma. Guided by over 40 key opinion leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress will provide a stimulating and interactive forum for attendees from all relevant medical specialties who are interested in the developments that lead to improved patient care.

Learning Objectives:
After attending this conference, participants should be able to:
1. Have increased awareness/knowledge regarding:
•    Biological pathways in hematological malignancies and their therapeutic implications
•    The biology of bone disease in myeloma and the evolving role of bisphosphonates and other anti-RANKL agents in patient care
•    The implications of recent clinical investigations into improving standard therapy for lymphoma and other hematological malignancies
•    Novel therapies on the horizon, including HDAC inhibitors, new generation IMiDs, and proteasome inhibitors, and how to best use them in lymphoma and myeloma
2. Have increased confidence in their ability to:
•    Address challenging issues surrounding the use of transplantation including determining which patients it would benefit, optimal timing, and whether it is necessary as frontline therapy in myeloma
•    Adequately evaluate clinical situations in which maintenance therapy should be used in myeloma and lymphoma
•    Create optimal therapeutic plans for younger and elderly patients with CLL
•    Evaluate the potential of new treatment strategies for relapsed aggressive lymphoma for recent clinical investigations for both transplant-eligible and ineligible patients
3. Increased their planned (compared with current) frequency of use of:
•    Enrollment in clinical trials of promising novel agents for hematologic malignancies